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medication reconciliation, and medication access. This study has a pre-post design 
with control sites to provide scientific evidence of the clinical and economic impact 
of the interventions. The data collected includes measures of health outcomes, 
medication-related problems, and pharmacist interventions. Results: 3,001 
unique patients were seen by the pharmacy teams during the initial 13 months. A 
majority of these patients suffer from uncontrolled diabetes, hypertension or both. 
For patients with baseline A1C> 9%, 30% achieved A1C < 8% in the intervention group 
versus 13% in the control group after 180 days. For patients with initial BP > 140/90, 
87% of patients in the intervention group achieved BP < 140/90 within 45 days. 19,696 
medication-related problems were documented for 1,993 patients. Problems were 
categorized into four groups including appropriateness/effectiveness(43%), medica-
tion safety(18%), medication nonadherence/misuse(27%), and miscellaneous(9%). 
2,150 potential adverse drug events (pADEs) were identified and resolved for patients 
seen by the clinical pharmacy teams. The most common pADEs were excessive dos-
ing, adverse drug reactions, and polypharmacy. ConClusions: The integration of 
clinical pharmacy teams into the patient-centered medical home improves health 
outcomes and medication safety.
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objeCtives: This study aims to analyze the profile of psychiatric hospitalizations 
within the public health service in Brazil between 2010 and 2012, analyzing the main 
causes of hospitalization, according to the International Classification of Diseases 
(WHO CID.10), the profile of patient and place of residence in Brazil. Methods: Is 
a descriptive study on the profile of psychiatric hospitalizations within the public 
system of Brazil present in the database of the Hospital Information System (HIS) of 
the Ministry of Health from January 2010 to December 2012. Results: Data analysis 
showed that there was no significant change in the number of cases between 2010 
and 2012; the total number has remained at an average of 280.150 admissions per 
year. Remained the same profile of hospitalization: the majority of were for males 
(65%), 40% white, 26% brown and 6% black, and 28% of hospitalized patients do not 
report skin color. The most admissions occurred between the ages of 30 and 49 years 
(50%).Regarding the causes of hospitalization, classified according to ICD-10 (F00-
F99), the pattern found was 35% of the causes of hospitalization for schizophrenia, 
20% are disorders related to alcohol use, 18% are related disorders psychotropic and 
18% are mood disorders. Other causes, such as dementia, and others appear less 
than 5% of cases each. Regarding the profile of admissions by place of residence, it 
was observed that the more developed regions of the country had the highest per-
centage of hospitalizations, Southeast (42%) and South (28%). ConClusions: This 
study show that use of secondary data in surveys, from information system health, 
plus the low cost generated, an important source of epidemiological information, 
especially in countries with universal coverage of public health services such as 
Brazil , in which the majority of the population depends on the public health system.
PHS15
PnEumococcal VaccinE targEting StratEgy for tHE oldEr adultS: 
cuStomizEd riSk Profiling
Balicer RD1, Cohen C1, Leibowitz M1, Feldman B1, Brufman I1, Roberts CS2, Hoshen M1
1Clalit Health Services, Tel Aviv, Israel, 2Pfizer Inc., New York, NY, USA
objeCtives: Current pneumococcal vaccine campaigns take a broad, primarily age-
based approach to immunization targeting, overlooking many clinical and admin-
istrative considerations necessary in disease prevention and resource planning for 
specific patient populations. We aim to demonstrate the utility of a population-
specific predictive model for hospital-treated pneumonia to direct effective vaccine 
targeting. Methods: Data was extracted for 1,053,435 members of an Israeli HMO, 
age 50 and older, during the study period 2008-2010. We developed and validated 
a logistic regression model to predict hospital-treated pneumonia using training 
and test samples, including a set of standard and population-specific risk factors. 
The model’s predictive value was tested for prospectively identifying cases of pneu-
monia and invasive pneumococcal disease (IPD), and was compared to the existing 
international paradigm for patient immunization targeting. Results: In a multi-
variate regression, age, co-morbidity burden and previous pneumonia events were 
most strongly positively associated with hospital-treated pneumonia. The model 
predicting hospital-treated pneumonia yielded a c-statistic of 0.80. Utilizing the 
predictive model, the top 17% highest-risk within the study validation population 
were targeted to detect 54% of those members who were subsequently treated for 
hospitalized pneumonia in the follow up period. The high-risk population identi-
fied through this model included 46% of the follow-up year’s IPD cases, and 27% of 
community-treated pneumonia cases. These outcomes were compared with inter-
national guidelines for risk for pneumococcal diseases that accurately identified 
only 35% of hospitalized pneumonia, 41% of IPD cases and 21% of community-
treated pneumonia. ConClusions: We demonstrate that a customized model for 
vaccine targeting performs better than international guidelines, and therefore, risk 
modeling may allow for more precise vaccine targeting and resource allocation than 
current national and international guidelines. Health care managers and policy-
makers may consider the strategic potential of utilizing clinical and administra-
tive databases for creating population-specific risk prediction models to inform 
vaccination campaigns.
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events (N= 9 of 12, 75 %). This may contribute to improved health care utilization, as 
measured by the lower rates of hospitalization or emergency department visits (N= 7, 
78%). PMAS also resulted in cost-savings in seven of the studies. ConClusions: 
Pharmacist-lead outpatient anticoagulation services attained better quality of anti-
coagulation control, lower bleeding and thromboembolic events, and lower health 
care utilization.
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objeCtives: To investigate whether Home Medication Review (HMR) conducted 
by a pharmacist can improve the clinical indices, quality of life and medication 
adherence in patients with Type 2 Diabetes Mellitus (T2DM). Methods: Six month 
prospective, randomized, controlled study. Adult T2DM patients taking medications 
for diabetes for at least two years, with HbA1c> 8%, were recruited into the study 
and randomized to intervention or control. The intervention group received three 
home visits by a pharmacist (at baseline, 3 months and at 6 months), and one group 
counselling session with a dietician in addition to the standard medical care. Control 
group patients only received standard medical care. Primary outcome measures 
were HbA1c and fasting blood sugar (FBS). Secondary outcome measures include 
lipid profile (triglycerides, LDL- and HDL-cholesterol); blood pressure (BP); medi-
cation adherence (assessed using modified Morisky adherence scale); and qual-
ity of life (QoL) assessed using the Short form health survey (SF-36v2). Outcomes 
were evaluated at baseline, 3 months and at 6 months. Results: 73 patients were 
recruited and randomized to the intervention group (38) or the control group (35), 
with no significant difference identified in baseline parameters. Data was analysed 
in SPSSv19(IBM) using ANOVA and paired t-test. There were significant improve-
ments from baseline to 6 months in the intervention group in; HbA1c (mean dif-
ference (MD) = 1.57, 95% CI[0.88, 2.26], p< 0.001); FBS (MD= 2.76, 95% CI[0.59,4.94], 
p= 0.009); systolicBP (MD= 6.56, 95% CI[0.75,12.36], p= 0.022); diastolicBP (MD= 4.44, 
95% CI[1.11,7.78], p= 0.006); triglycerides (MD= 0.59, 95% CI[0.24,0.93], p< 0.001) and 
medication adherence (MD= -2.19, 95% CI[-2.73,-1.65], p< 0.001). The control group 
showed no significant changes in outcome measures. QoL improved in the interven-
tion group but declined in controls. ConClusions: In this study, HMR conducted by 
a pharmacist provided significant improvement in health and QoL of patients with 
Type 2 Diabetes Mellitus. HMR may be beneficial for patients with chronic diseases 
and for the health care system.
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objeCtives: Hepatitis B co-infection may lead to increased mortality of HIV 
patients. All HIV-infected patients are recommended to receive hepatitis B virus 
(HBV) vaccination to prevent the co-infection. However, HIV-infected patients often 
fail to produce protective antibodies to HBV vaccine. This study is sought to assess 
the efficacy of increased-dose HBV vaccine in HIV-infected patients. Methods: A 
systematic literature review and meta-analysis of clinical trials were conducted. 
The search was carried out on PubMed, EMBASE and the Cochran Database of 
Systematic Reviews, from beginning of databases to December 2013. Keywords 
used in the electronic searches included “hepatitis b”, “HBV”, “vaccine”, “vaccina-
tion”, “immunization”, “HIV”, and “ADIS”. We only included studies those published 
in full-text papers. Inclusion criteria are as follows: English language and rand-
omized control trials those compare the response rates of increased-dose HBV 
vaccine (increase dose or administration times of standard dose) and standard-
dose vaccine (20μ g 3 times at month 0, 1, and 6) in HIV-infected patients. Random 
effect model with heterogeneity analyses were used. The result was reported by 
risk ratio. Statistical analyses were performed using the software program Review 
Manager 5.2. Results: Of 1204 references yielded by electronic searches, five 
trials, which represent a total of 424 patients, were included in the final analysis. 
The heterogeneity was moderate (I2= 32%) according to the I42 test. Pooling of 
study results showed a significant increase in response rate among increased-
dose patients versus control patients; the pooled risk ratio (RR) was 1.17 (95% CI: 
1.06-1.30). The number of intent-to-treat is 9. Only one study presented severe 
adverse reaction reports related to the vaccination, and no increased risk was 
observed. ConClusions: Increasing the dosage of vaccine may improve the 
immune responses significantly in HIV-infected patients.
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objeCtives: Medications must be prescribed and administered properly to be effec-
tive for the treatment of chronic conditions. Medication errors and poor adherence 
lead to increased costs and poor outcomes. Evidence shows that clinical outcomes 
improve when pharmacists are integrated into the care team. The objectives of this 
study were to improve health care quality, medication safety, and reduce health 
care costs for high-risk patients through the integration of clinical pharmacy ser-
vices into patient-centered medical homes. Methods: Clinical pharmacy teams 
consisting of a pharmacist, resident, and pharmacy technician were integrated into 
five safety net clinics starting in September 2012. Five additional sites were added 
in October 2013. These teams target high-risk patients with poor chronic disease 
control. The services provided include medication and disease state management, 
